CR20170496A - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Info

Publication number
CR20170496A
CR20170496A CR20170496A CR20170496A CR20170496A CR 20170496 A CR20170496 A CR 20170496A CR 20170496 A CR20170496 A CR 20170496A CR 20170496 A CR20170496 A CR 20170496A CR 20170496 A CR20170496 A CR 20170496A
Authority
CR
Costa Rica
Prior art keywords
vivic
sulfonimidoilpurinone
profilaxis
infections
derivatives
Prior art date
Application number
CR20170496A
Other languages
English (en)
Inventor
Kun; Miao
Chungen Liang
Hongying; Yun
Xiufang; Zheng
Jianping Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170496(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20170496A publication Critical patent/CR20170496A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), en la que R1, R2 y R3 son como se han descrito en el presente documento, y sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.
CR20170496A 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas CR20170496A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
CR20170496A true CR20170496A (es) 2017-12-05

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170496A CR20170496A (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Country Status (32)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR102690131B1 (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX376761B (es)
MY (1) MY182353A (es)
NZ (2) NZ735648A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI768467B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX376761B (es) 2015-05-08 2025-03-07 Hoffmann La Roche Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas.
KR102459155B1 (ko) * 2016-08-29 2022-10-28 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 및 예방을 위한 7-치환된 설폰이미도일푸린온 화합물
PL3512556T3 (pl) * 2016-09-13 2021-12-27 F. Hoffmann-La Roche Ag Leczenie skojarzone agonistą TLR7 i inhibitorem składania kapsydu HBV
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2020008746A (es) * 2018-02-28 2020-09-28 Hoffmann La Roche Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
AU2020223031B2 (en) * 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
EP4031544B1 (en) 2019-09-20 2024-02-28 Syngenta Crop Protection AG Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132592A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN119604517A (zh) 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
MX366481B (es) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
LT3190113T (lt) 2014-08-15 2021-08-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
MX376761B (es) * 2015-05-08 2025-03-07 Hoffmann La Roche Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas.
KR102459155B1 (ko) * 2016-08-29 2022-10-28 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 및 예방을 위한 7-치환된 설폰이미도일푸린온 화합물

Also Published As

Publication number Publication date
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
US20160326177A1 (en) 2016-11-10
EP3294740A1 (en) 2018-03-21
US20200109144A1 (en) 2020-04-09
TWI706954B (zh) 2020-10-11
IL280769B1 (en) 2023-03-01
NZ775222A (en) 2024-09-27
SI3294740T1 (sl) 2019-12-31
US10399983B2 (en) 2019-09-03
CN107580596A (zh) 2018-01-12
NZ735648A (en) 2023-06-30
HK1247925A1 (zh) 2018-10-05
PL3294740T3 (pl) 2020-03-31
RS59435B1 (sr) 2019-11-29
IL254947B (en) 2021-02-28
BR112017023959A2 (pt) 2018-07-17
PT3294740T (pt) 2019-10-29
IL254947A0 (en) 2017-12-31
PE20171620A1 (es) 2017-11-02
HRP20191942T1 (hr) 2020-01-10
CL2017002745A1 (es) 2018-05-18
AU2016260683B2 (en) 2020-10-29
SG10202108841YA (en) 2021-09-29
AU2020256348B2 (en) 2022-06-16
KR20180003612A (ko) 2018-01-09
EP3294740B1 (en) 2019-09-04
MX393198B (es) 2025-03-19
ES2753777T3 (es) 2020-04-14
AU2022204666A1 (en) 2022-07-21
AU2016260683A1 (en) 2017-10-12
MX2017014033A (es) 2018-03-01
KR102690131B1 (ko) 2024-07-31
MY182353A (en) 2021-01-20
AR104528A1 (es) 2017-07-26
CN107580596B (zh) 2020-07-14
JP6738352B2 (ja) 2020-08-12
UA120450C2 (uk) 2019-12-10
JP2018515509A (ja) 2018-06-14
WO2016180695A1 (en) 2016-11-17
CA2982704C (en) 2023-10-24
US9708325B2 (en) 2017-07-18
IL280769B2 (en) 2023-07-01
TWI768467B (zh) 2022-06-21
TW201716410A (zh) 2017-05-16
MX2020010949A (es) 2022-06-16
AU2020256348A1 (en) 2020-11-12
DK3294740T3 (da) 2019-11-04
PH12017502009A1 (en) 2018-03-26
IL280769A (en) 2021-04-29
US20170275286A1 (en) 2017-09-28
LT3294740T (lt) 2019-11-25
RU2017142577A3 (es) 2019-10-31
MX376761B (es) 2025-03-07
CO2017009994A2 (es) 2018-02-20
US11242345B2 (en) 2022-02-08
HUE045906T2 (hu) 2020-01-28
CA2982704A1 (en) 2016-11-17
BR112017023959B1 (pt) 2023-05-02
RU2017142577A (ru) 2019-06-10

Similar Documents

Publication Publication Date Title
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
MX2023001876A (es) Derivados de rapamicina.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
MX2018000282A (es) Oxiesteroles y metodos de uso de los mismos.
DOP2017000278A (es) Piridinas sustituidas y método de uso
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
PY1515461A (es) Derivados de Dihidropirrolopirimidina
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
NI201600171A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida
ECSP11010817A (es) Agentes antifúngicos